(HealthDay)—Taken every other day, rimegepant demonstrates efficacy for the preventive treatment of migraine, according to a study published online Dec. 15 in The Lancet. Robert Croop, M.D., from Biohaven Pharmaceuticals in New Haven, Connecticut, and colleagues compared the efficacy of…
Read More
Nemolizumab beats placebo for reduction of pruritus in eczema
(HealthDay)—For patients with atopic dermatitis and moderate-to-severe pruritus, nemolizumab results in a greater reduction in pruritus than placebo, according to a study published in the July 9 issue of the New England Journal of Medicine. Kenji Kabashima, M.D., Ph.D., from…
Read More
Teprotumumab bests placebo for active thyroid eye disease
(HealthDay)—Teprotumumab is associated with better outcomes than placebo among patients with active thyroid eye disease, according to a study published in the Jan. 23 issue of the New England Journal of Medicine. Raymond S. Douglas, M.D., Ph.D., from the Cedars-Sinai…
Read More